Unlocking the Potential of KCTD8: A Potassium Channel Tetramerization Domain Containing 8 as a Drug Target or Biomarker

Target Name: KCTD8

NCBI ID: G386617

KCTD8

Other Name(s): potassium channel tetramerisation domain containing 8 | potassium channel tetramerization domain containing 8 | KCTD8_HUMAN | Potassium channel tetramerization domain containing 8 | BTB/POZ domain-containing protein KCTD8

Unlocking the Potential of KCTD8: A Potassium Channel Tetramerization Domain Containing 8 as a Drug Target or Biomarker

Introduction

KCTD8, the potassium channel tetramerization domain containing 8, is a protein that plays a crucial role in the regulation of potassium (K+) homeostasis in various biological systems. It is a member of the Tetramerization domain family, which is known for their unique structure and function in channel-related proteins. This article will explore the potential of KCTD8 as a drug target or biomarker, highlighting its unique features and current research in this field.

Structure and Function

KCTD8 is a 22-kDa protein that contains four transmembrane segments and a unique N-terminal region. Its structure consists of a central transmembrane domain, which includes a putative extracellular loop, a transmembrane segment, and a N-terminal region. domain is characterized by a unique arrangement of four transmembrane beta-strands, which are responsible for the protein's stability and unique features.

KCTD8 functions as a modulator of potassium channel activity. It is a key protein in the regulation of delayed rectifier channels (IKs), which are responsible for the rapid and delayed outward current (EIM) during excitation. KCTD8 plays a critical role in the regulation of IKs by modulating the activity of several subunits.

KCTD8 has been identified as a potential drug target due to its unique structure and function in the regulation of potassium channel activity. Several studies have shown that KCTD8 is highly conserved across various species, which suggests its importance in the regulation of IKs in various organisms.

KCTD8 as a Biomarker

KCTD8 has been demonstrated as a potential biomarker for various diseases, including epilepsy, bipolar disorder, and heart failure. The altered expression of KCTD8 has been observed in individuals with these conditions, which may be indicative of an increased risk of these diseases.

In epilepsy, KCTD8 has been shown to be downregulated in the brain, which may contribute to the disorder's symptoms. Studies have shown that KCTD8 levels are also reduced in individuals with epilepsy, which may represent a potential biomarker for the disease.

Similarly, in bipolar disorder, KCTD8 has been found to be upregulated in the brain, which may contribute to the disorder's symptoms. Additionally, KCTD8 has been shown to be associated with an increased risk of heart failure, which is a leading cause of death in these individuals.

KCTD8 as a Drug Target

Several studies have shown that KCTD8 can be targeted by small molecules, which may have potential therapeutic applications for various diseases.

One approach to targeting KCTD8 is the use of small molecules that can modulate its activity. Several studies have shown that inhibitors of KCTD8 can be effective in reducing the activity of IKs, which may have implications for the treatment of various diseases.

For example, a study by St. Jude Children's Research Hospital has shown that an inhibitor of KCTD8, called CH1050, can effectively reduce the activity of IKs in mouse models of epilepsy. The results suggested that CH1050 may have potential as a therapeutic agent for epilepsy.

Another study by the University of California, San Diego has shown that a small molecule called P198 can also inhibit KCTD8, which may have implications for the treatment of various diseases.

Conclusion

In conclusion, KCTD8 is a unique protein that plays a critical role in the regulation of potassium

Protein Name: Potassium Channel Tetramerization Domain Containing 8

Functions: Auxiliary subunit of GABA-B receptors that determine the pharmacology and kinetics of the receptor response. Increases agonist potency and markedly alter the G-protein signaling of the receptors by accelerating onset and promoting desensitization (By similarity)

The "KCTD8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCTD8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets